-
1
-
-
0035811625
-
Hepatitis C virus infection
-
Lauer GM, Walker BD. Hepatitis C virus infection. N EnglJ Med 2001;345:41-52.
-
(2001)
N EnglJ Med
, vol.345
, pp. 41-52
-
-
Lauer, G.M.1
Walker, B.D.2
-
2
-
-
30044432484
-
American Gastroenterolog-ical Association technical review on the management of hepatitis C
-
Dienstag JL, McHutchison JG. American Gastroenterolog-ical Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-64.
-
(2006)
Gastroenterology
, vol.130
, pp. 231-64
-
-
Dienstag, J.L.1
McHutchison, J.G.2
-
3
-
-
0036242165
-
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
-
Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
-
(2002)
Gastroenterology
, vol.122
, pp. 1303-13
-
-
Poynard, T.1
McHutchison, J.2
Manns, M.3
Trepo, C.4
Lindsay, K.5
Goodman, Z.6
-
4
-
-
1842479859
-
Diagnosis, management, and treatment of hepatitis C
-
Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-71.
-
(2004)
Hepatology
, vol.39
, pp. 1147-71
-
-
Strader, D.B.1
Wright, T.2
Thomas, D.L.3
Seeff, L.B.4
-
5
-
-
10744225023
-
A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C
-
Fattovich G, Zagni I, Minola E, Felder M, Rovere P, Carlotto A, et al. A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. J Hepatol 2003;39:843-9.
-
(2003)
J Hepatol
, vol.39
, pp. 843-9
-
-
Fattovich, G.1
Zagni, I.2
Minola, E.3
Felder, M.4
Rovere, P.5
Carlotto, A.6
-
6
-
-
0031945834
-
Re-treatment of chronic hepatitis C with consensus interferon
-
Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27:1136-43.
-
(1998)
Hepatology
, vol.27
, pp. 1136-43
-
-
Heathcote, E.J.1
Keeffe, E.B.2
Lee, S.S.3
Feinman, S.V.4
Tong, M.J.5
Reddy, K.R.6
-
7
-
-
0032786260
-
Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: Effect of baseline viral concentration. Consensus Interferon Study Group
-
Jensen DM, Krawitt EL, Keeffe EB, Hollinger FB, James SP, Mullen K, et al. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group. Am J Gastroenterol 1999;94: 3583-8.
-
(1999)
Am J Gastroenterol
, vol.94
, pp. 3583-8
-
-
Jensen, D.M.1
Krawitt, E.L.2
Keeffe, E.B.3
Hollinger, F.B.4
James, S.P.5
Mullen, K.6
-
8
-
-
0030886965
-
Therapy of hepatitis C: Consensus interferon trials. Consensus Interferon Study Group
-
Keeffe EB, Hollinger FB. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group. Hepa-tology 1997;26:101S-107S.
-
(1997)
Hepatology
, vol.26
-
-
Keeffe, E.B.1
Hollinger, F.B.2
-
9
-
-
17644415729
-
Interferon alfacon-1 and riba-virin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C
-
Sjogren MH, Sjogren R, Holtzmuller K, Winston B, Butterfield B, Drake S, et al. Interferon alfacon-1 and riba-virin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. Dig Dis Sci 2005;50:727-32.
-
(2005)
Dig Dis Sci
, vol.50
, pp. 727-32
-
-
Sjogren, M.H.1
Sjogren, R.2
Holtzmuller, K.3
Winston, B.4
Butterfield, B.5
Drake, S.6
-
10
-
-
20244372974
-
A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lym-phoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection
-
Suzuki H, Tango T. A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lym-phoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection. Hepatol Res 2002;22: 1-12.
-
(2002)
Hepatol Res
, vol.22
, pp. 1-12
-
-
Suzuki, H.1
Tango, T.2
-
11
-
-
0031914792
-
Treatment of chronic hepatitis C virus infection with recombinant consensus interferon
-
Tong MJ, Blatt LM, Resser KJ, Klein MC, Cruickshank SE, Figueroa T, et al. Treatment of chronic hepatitis C virus infection with recombinant consensus interferon. J Interferon Cytokine Res 1998;18:81-6.
-
(1998)
J Interferon Cytokine Res
, vol.18
, pp. 81-6
-
-
Tong, M.J.1
Blatt, L.M.2
Resser, K.J.3
Klein, M.C.4
Cruickshank, S.E.5
Figueroa, T.6
-
12
-
-
0345695221
-
Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial. Consensus Interferon Study Group
-
Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 1997; 26:747-54.
-
(1997)
Hepatology
, vol.26
, pp. 747-54
-
-
Tong, M.J.1
Reddy, K.R.2
Lee, W.M.3
Pockros, P.J.4
Hoefs, J.C.5
Keeffe, E.B.6
-
13
-
-
0030886964
-
-
National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C
-
National Institutes of Health Consensus Development Con-ference Panel statement: management of hepatitis C. Hepa-tology 1997;26:2S-10S.
-
(1997)
Hepatology
, vol.26
-
-
-
14
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales Jr FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N EnglJ Med 2002;347: 975-82.
-
(2002)
N EnglJ Med
, vol.347
, pp. 975-82
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
Smith, C.4
Marinos, G.5
Goncales Jr., F.L.6
-
15
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
-
(2001)
Lancet
, vol.358
, pp. 958-65
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
Rustgi, V.K.4
Shiffman, M.5
Reindollar, R.6
-
16
-
-
0026563204
-
Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources
-
Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73:673-9.
-
(1992)
J Gen Virol
, vol.73
, pp. 673-9
-
-
Okamoto, H.1
Sugiyama, Y.2
Okada, S.3
Kurai, K.4
Akahane, Y.5
Sugai, Y.6
-
17
-
-
84989530085
-
Significance of specific anti-body assay for genotyping of hepatitis C virus
-
Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, et al. Significance of specific anti-body assay for genotyping of hepatitis C virus. Hepatology 1994;19:1347-53.
-
(1994)
Hepatology
, vol.19
, pp. 1347-53
-
-
Tanaka, T.1
Tsukiyama-Kohara, K.2
Yamaguchi, K.3
Yagi, S.4
Tanaka, S.5
Hasegawa, A.6
-
18
-
-
8544229103
-
Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group
-
Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997;113: 558-66.
-
(1997)
Gastroenterology
, vol.113
, pp. 558-66
-
-
Shiratori, Y.1
Kato, N.2
Yokosuka, O.3
Imazeki, F.4
Hashimoto, E.5
Hayashi, N.6
-
19
-
-
0028235641
-
Classification of chronic hepatitis: Diagnosis, grading and staging
-
Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
-
(1994)
Hepatology
, vol.19
, pp. 1513-20
-
-
Desmet, V.J.1
Gerber, M.2
Hoofnagle, J.H.3
Manns, M.4
Scheuer, P.J.5
-
20
-
-
33845641280
-
Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy
-
Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006;44: 1598-1606.
-
(2006)
Hepatology
, vol.44
, pp. 1598-1606
-
-
Del Rio, R.A.1
Post, A.B.2
Singer, M.E.3
-
21
-
-
0032731788
-
Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C
-
Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999;30:1318-24.
-
(1999)
Hepatology
, vol.30
, pp. 1318-24
-
-
Younossi, Z.M.1
Singer, M.E.2
McHutchison, J.G.3
Shermock, K.M.4
-
22
-
-
1542378867
-
Peginterferon-alpha2a and ribavirin com-bination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
-
Hadziyannis SJ, Sette Jr H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin com-bination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
-
(2004)
Ann Intern Med
, vol.140
, pp. 346-55
-
-
Hadziyannis, S.J.1
Sette Jr., H.2
Morgan, T.R.3
Balan, V.4
Diago, M.5
Marcellin, P.6
-
23
-
-
0032547938
-
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
-
McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
-
(1998)
N Engl J Med
, vol.339
, pp. 1485-92
-
-
McHutchison, J.G.1
Gordon, S.C.2
Schiff, E.R.3
Shiffman, M.L.4
Lee, W.M.5
Rustgi, V.K.6
-
24
-
-
2442683905
-
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previ-ously untreated patients infected with HCV genotypes 2 or 3
-
Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previ-ously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-9.
-
(2004)
J Hepatol
, vol.40
, pp. 993-9
-
-
Zeuzem, S.1
Hultcrantz, R.2
Bourliere, M.3
Goeser, T.4
Marcellin, P.5
Sanchez-Tapias, J.6
-
25
-
-
79955601866
-
United States life tables 2006
-
Arias E. United States life tables, 2006. Natl Vital Stat Rep 2010;58:1-40.
-
(2010)
Natl Vital Stat Rep
, vol.58
, pp. 1-40
-
-
Arias, E.1
-
27
-
-
0030720484
-
Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C
-
Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127: 855-65.
-
(1997)
Ann Intern Med
, vol.127
, pp. 855-65
-
-
Bennett, W.G.1
Inoue, Y.2
Beck, J.R.3
Wong, J.B.4
Pauker, S.G.5
Davis, G.L.6
-
28
-
-
0035700211
-
Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults
-
Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 2001;111:667-8.
-
(2001)
Am J Med
, vol.111
, pp. 667-8
-
-
Singer, M.E.1
Younossi, Z.M.2
-
29
-
-
0032583497
-
Pretreatment evaluation of chronic hepatitis C: Risks, benefits, and costs
-
Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998;280:2088-93.
-
(1998)
JAMA
, vol.280
, pp. 2088-93
-
-
Wong, J.B.1
Bennett, W.G.2
Koff, R.S.3
Pauker, S.G.4
-
30
-
-
0035120575
-
Assessment of utilities and health-related quality of life in patients with chronic liver disease
-
Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastro-enterol 2001;96:579-83.
-
(2001)
Am J Gastro-enterol
, vol.96
, pp. 579-83
-
-
Younossi, Z.M.1
Boparai, N.2
McCormick, M.3
Price, L.L.4
Guyatt, G.5
-
31
-
-
0037345686
-
Health-state utilities and quality of life in hepatitis C patients
-
Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98: 630-8.
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 630-8
-
-
Chong, C.A.1
Gulamhussein, A.2
Heathcote, E.J.3
Lilly, L.4
Sherman, M.5
Naglie, G.6
-
32
-
-
0037372609
-
Cost effectiveness of peginter-feron alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C
-
Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of peginter-feron alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425-32.
-
(2003)
Gut
, vol.52
, pp. 425-32
-
-
Siebert, U.1
Sroczynski, G.2
Rossol, S.3
Wasem, J.4
Ravens-Sieberer, U.5
Kurth, B.M.6
-
33
-
-
0033056294
-
Efficacy of interferon alfacon-1 daily induction therapy followed by three-times weekly therapy in patients with chronic hepatitis C virus infection with high and low viral titers
-
Suzuki H, Iino S, Omata M, Kumada H, Hino K. Efficacy of interferon alfacon-1 daily induction therapy followed by three-times weekly therapy in patients with chronic hepatitis C virus infection with high and low viral titers. Hepatol Res 1999;15:64-79.
-
(1999)
Hepatol Res
, vol.15
, pp. 64-79
-
-
Suzuki, H.1
Iino, S.2
Omata, M.3
Kumada, H.4
Hino, K.5
-
34
-
-
0032585237
-
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
-
Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352: 1426-32
-
(1998)
Lancet
, vol.352
, pp. 1426-32
-
-
Poynard, T.1
Marcellin, P.2
Lee, S.S.3
Niederau, C.4
Minuk, G.S.5
Ideo, G.6
-
35
-
-
0037564237
-
-
National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (10-12 June 2002)
-
National Institutes of Health Consensus Development Con-ference Statement: Management of hepatitis C 2002 (10-12 June 2002). Gastroenterology 2002;123:2082-99.
-
(2002)
Gastroenterology
, vol.123
, pp. 2082-99
-
-
-
36
-
-
0032547944
-
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group
-
Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
-
(1998)
N Engl J Med
, vol.339
, pp. 1493-9
-
-
Davis, G.L.1
Esteban-Mur, R.2
Rustgi, V.3
Hoefs, J.4
Gordon, S.C.5
Trepo, C.6
-
37
-
-
33644804915
-
Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C
-
Iwasaki Y, Ikeda H, Araki Y, Osawa T, Kita K, Ando M, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43:54-63.
-
(2006)
Hepatology
, vol.43
, pp. 54-63
-
-
Iwasaki, Y.1
Ikeda, H.2
Araki, Y.3
Osawa, T.4
Kita, K.5
Ando, M.6
-
38
-
-
0031041924
-
Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
-
Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
-
(1997)
Gastroenterology
, vol.112
, pp. 463-72
-
-
Fattovich, G.1
Giustina, G.2
Degos, F.3
Tremolada, F.4
Diodati, G.5
Almasio, P.6
-
39
-
-
0030671562
-
Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C
-
Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997;127:866-74.
-
(1997)
Ann Intern Med
, vol.127
, pp. 866-74
-
-
Kim, W.R.1
Poterucha, J.J.2
Hermans, J.E.3
Therneau, T.M.4
Dickson, E.R.5
Evans, R.W.6
-
40
-
-
1642484544
-
Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990
-
Krahn M, Wong JB, Heathcote J, Scully L, Seeff L. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Making 2004;24:20-9.
-
(2004)
Med Decis Making
, vol.24
, pp. 20-9
-
-
Krahn, M.1
Wong, J.B.2
Heathcote, J.3
Scully, L.4
Seeff, L.5
-
41
-
-
0028275912
-
Liver transplantation for hepatitis C virus-related cirrhosis
-
Ascher NL, Lake JR, Emond J, Roberts J. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994;20:24S-27S.
-
(1994)
Hepatology
, vol.20
-
-
Ascher, N.L.1
Lake, J.R.2
Emond, J.3
Roberts, J.4
-
43
-
-
0027458066
-
An analysis of liver transplant experience from 37 transplant centers as reported to Medicare
-
Kilpe VE, Krakauer H, Wren RE. An analysis of liver transplant experience from 37 transplant centers as reported to Medicare. Transplantation 1993;56:554-61.
-
(1993)
Transplantation
, vol.56
, pp. 554-61
-
-
Kilpe, V.E.1
Krakauer, H.2
Wren, R.E.3
-
44
-
-
3242750664
-
Survival after liver transplantation in the United States: A disease-specific analysis of the UNOS database
-
Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 2004;10:908-10.
-
(2004)
Liver Transpl
, vol.10
, pp. 908-10
-
-
Roberts, M.S.1
Angus, D.C.2
Bryce, C.L.3
Valenta, Z.4
Weissfeld, L.5
-
45
-
-
0025887360
-
Hepatocellular carcinoma in Italian patients with cirrhosis
-
Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N EnglJ Med 1991;325:729-31.
-
(1991)
N EnglJ Med
, vol.325
, pp. 729-31
-
-
Colombo, M.1
De Franchis, R.2
Del Ninno, E.3
Sangiovanni, A.4
De Fazio, C.5
Tommasini, M.6
-
46
-
-
0027243462
-
Risk factors for hepatocellular carcinoma among patients with chronic liver disease
-
Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;329:1896-7.
-
(1993)
N Engl J Med
, vol.329
, pp. 1896-7
-
-
Tsukuma, H.1
Hiyama, T.2
Tanaka, S.3
Nakao, M.4
Yabuuchi, T.5
Kitamura, T.6
|